6 citations
,
June 2018 in “PLOS ONE” The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.
1 citations
,
August 2025 Drug repurposing can speed up and reduce costs in drug discovery, especially for cancer treatment.
Defective protein folding due to a mutation is key in ANE syndrome.
April 2026 in “Diagnostics” Parry–Romberg Syndrome can involve the brain even without obvious symptoms, and a new diagnostic framework is suggested for early detection.
76 citations
,
January 1998 in “Mammalian Genome”
3 citations
,
December 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” PRP improves short-term pain and function in shoulder injuries, but long-term benefits are unclear.
24 citations
,
July 1994 in “Journal of Investigative Dermatology” January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
January 2022 in “Figshare” Activated PRP is unnecessary for treating alopecia areata; both activated and non-activated PRP are equally effective and safe.
January 2014 in “Medical Innovation of China” Androgen receptor differences may contribute to hair loss in AGA patients.